Get the information you need to ensure your European market access strategy is heading in the right direction.
It was less than a decade ago that most pharmaceutical manufacturers considered market access the last step in the commercialization process. However access is being managed ever more tightly with payers increasingly establishing evidence-based care paths and therapeutic guidelines.
Payers are now a significant player in product commercialization and companies need to rethink their business models. In this white paper we explore how the G-5 European countries have faced these challenges.
These +15 pages will give you: